Illumina (ILMN) stock slides 10% after 2026 outlook puts China, research demand back in focus

Illumina tumbled 10.3% to $119.91 on Friday, hitting a low of $117.69, as investors digested the gene-sequencing company’s 2026 forecast released alongside its earnings.

Abbott (ABT) stock price steadies after Barclays trims target; Exact Sciences vote is next key date

Abbott (ABT) stock price steadies after Barclays trims target; Exact Sciences vote is next key date

Abbott Laboratories shares were last up 0.1% at $109.43 on Monday after Barclays lowered its 12-month target price to $142 from $169, citing reduced estimates and a lower valuation multiple but keeping an Overweight rating. A price target is an analyst estimate; Overweight signals it expects the stock to outperform its coverage universe.
Thermo Fisher stock slides on 2026 profit outlook as research funding cuts bite — what’s next for TMO

Thermo Fisher stock slides on 2026 profit outlook as research funding cuts bite — what’s next for TMO

Shares of Thermo Fisher Scientific Inc fell 2.6% to close at $592.16 on Thursday, dropping more than Danaher, which was down 2.3%, and Agilent, down 0.4%. The decline came after the company forecast 2026 profits below Wall Street expectations and flagged challenges from cuts to U.S. academic research funding. Thermo Fisher projected adjusted 2026 earnings between $24.22 and $24.80 per share, and revenue of $46.3 billion to $47.2 billion, compared with LSEG consensus estimates of $24.61 and $46.54 billion. CEO Marc Casper said the firm expects “similar conditions to last year” for academic and government clients. Bernstein analysts described the company’s 1% to 2% growth forecast for the first quarter as “soft.”
Denali Therapeutics stock price rises as FDA freezes rival Regenxbio’s Hunter syndrome gene therapy trials

Denali Therapeutics stock price rises as FDA freezes rival Regenxbio’s Hunter syndrome gene therapy trials

• Denali Therapeutics shares climbed in afternoon trading, gaining ground while the broader biotech sector remained flat.• Attention intensified following the FDA’s decision to halt Regenxbio’s rare-disease gene therapy trials.• Investors are now zeroed in on Denali’s FDA timeline for its Hunter syndrome treatment and the data update expected in early February.
1 6 7 8 9 10 22

US Stock Market Today Updates

AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 Strong Buy

NVIDIA

94/100
#2 Strong Buy

Meta Platforms

89/100
#3 Buy

Alphabet

87/100
#4 Buy

Amazon

84/100
#5 Selective Buy

Microsoft

82/100
View full portfolio
Editorial model selection. Not personalised advice.